Anixa Biosciences (ANIX) vs Corbus Pharmaceuticals (CRBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 34.5% versus a loss of 60.7%. Over five years, ANIX leads with a -33.7% price change compared with -82.8% for CRBP. Corbus Pharmaceuticals is the larger company by market cap ($101.9 million vs $101.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | CRBP |
|---|---|---|
| Share price | $2.91 | $5.27 |
| Market cap | $101.16M | $101.93M |
| 1-day change | -1.36% | -4.01% |
| YTD return | -6.73% | -35.26% |
| 1-year return | -34.46% | -60.73% |
| 5-year return | -33.71% | -82.78% |
| EPS (TTM) | $-0.32 | $-6.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $20.56 |
| 52-week low | $2.32 | $5.13 |
| Distance from 52-week high | -46.70% | -74.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +235.05% | +545.73% |
| Average volume | 302.95K | 756.54K |
| Shares outstanding | 34.76M | 19.34M |
| Employees | 4 | 36 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed CRBP by 26.3 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Healthcare · Biotechnology · 36 employees
ANIX vs CRBP FAQ
Which is bigger, Anixa Biosciences or Corbus Pharmaceuticals?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $101.93M compared with $101.16M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or CRBP?
ANIX returned -34.46% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Corbus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.